上海品茶

您的当前位置:上海品茶 > 报告分类 > PDF报告下载

智慧芽:2022中美口服新冠药对比&全球3CL抑制剂专利分析报告(69页).pdf

编号:88987 PDF 69页 4.24MB 下载积分:VIP专享
下载报告请您先登录!

智慧芽:2022中美口服新冠药对比&全球3CL抑制剂专利分析报告(69页).pdf

1、!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!#$%&()*!%&()!%!%#*+,-&./01!%!#!+*,-./012345*6!#%*+23456&7!%!$!#%#*+23489:;!6*,78-7/09:;123$&*=!$%!*?56ABCD89)!%!E!$%#!+?56ABCD89*?;!S*6AB!#CDETUVW*!X!G%HIJKLM$NO!#PQRST!%!U!G%VW$NO!#PQR!

2、%!E!G%#XVW$NO!#PQR!%!#!G%#YZ$NO!#PQRIJ!%!$F!G%#%2_Sa$NO!#PQRabcIJ!%!$F!#$%&()*+,-.!#$#/01()*+,-$!G%#%#d_SaIJ)!%!$#!#$2345,-#!#67289:;!#-67289?ABC9DE=(),-F!#G 67289HIJKLMNDE OPOQ,-R!#!,STUVWX,YZXZWWX,-R!#F,T_T,STUaTWb_ZTcX,-d!#R,eZfT,YZXZWWX,G.!#d,gbXZW,YZhTUaT,G.!#$.,iUjX_Tc,STUaT,G$!#$,eklmng,oWUTh

3、Wb_ZX,G#!#$#,pki,STUaT,G-!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!#$%&!#$#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!$%&(!)*+,#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!$#!()*+,-./01!$!%&-./01!2#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$%&-./345678#?!#$%&()*+,-*(./0+1.*23(4(

4、546.2780!?!G!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!U!#$%&()*+,-*(./0+1.*23(4(546.2780!?!E!%#!(23)2+,%4567-./$!?%!#%901:;347$#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!f!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!F!?%$#&901:;347$#?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!&#!8967%(!#:;?A!?!#$%&()*+,-*(./0+1.*23(4(54

5、6.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?)#!BCDE%(!#/F89GH!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!U!*#!%(!#:;FGF#FF$#FFe#FF#FFG#FFU#FFE#FFf#FF#F#F#F$#Fe#F#FG#FU#FE#Ff#F#F#F#F#!#

6、$%&()*+,-.FF#F$FeFFGFUFEFfFFF*?+?g?h?i?j?klmnL/012#$%&()*34!#$%&()*+,-*(./0+1.*23(4(546.2780!?!E!#!$%&!#$%?XVWo!Efo!GEpVWo!e#o!$#p567856#$%9:;&()*e#FF#F#$F+?*?h?j?56#$%9:;&()*134?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!f!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#F!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$

7、%&()*+,-*(./0+1.*23(4(546.2780!?!#!#(&!$%&!#$%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#$!?!#?$%&?()*?+,?-.?/01?234?5?6789?:3*?;91?234?ABCD?(E?FG4H?IJK.?!#?$%&?()*?+,?-.?/01?234?5?6789?:3*?;?ABCD?!#?$?%&?(?)*+?&,-#?./0?12?34?567?8094?:6;(?LMNAOPAQRS?ST?FG4H?IJK.?!#?$%&?()*?+,?-.?/01?234?ABCD?U?*?V?WX?Y3

8、?Z?X*?D_%?.?a?!#?$%&?6789*?:3?b?LMNAOPAQRS?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#U!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#E!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#f!?!#$%&()*+,-*(./0+1

9、.*23(4(546.2780!?!$F!&$JKLM%(!#EFGANO#!(#()*+$%&!#$%*+,-./0?!#$!#$%&%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!?!#$#()*#$%&%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$#!?!(1()*+23/045!#$+,-.%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$

10、!?!#/0+123456#$%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$U!?!#&/0+12789:2;?ABC;56#$%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$E!?!#)DEDF%?!#!%*+,-./%012/31.43./%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!$f!#5%64+47+%*8+,9+3.:713+;/%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!eF!

11、#+%012/31.43./%?!#?%:4/814.%012A8+,9+%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!#$B%C23,D/7+;%*8+,9+%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e#!?!#$%=EFGH%I8.,+A.:713/%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e$!#$#%JEC%*8+,9+%?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!ee!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!

12、#$%&()*+,-*(./0+1.*23(4(546.2780!?!eG!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!eU!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!eE!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!ef!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!F!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!#!?!#$%&()*+,-*(./0+1.*23(4(5

13、46.2780!?!$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!e!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!U!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!E!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!f!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!GF!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G#!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G$!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!Ge!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!G!?!#$%&()*+,-*(./0+1.*23(4(546.2780!?!GG!?https:/!

友情提示

1、下载报告失败解决办法
2、PDF文件下载后,可能会被浏览器默认打开,此种情况可以点击浏览器菜单,保存网页到桌面,就可以正常下载了。
3、本站不支持迅雷下载,请使用电脑自带的IE浏览器,或者360浏览器、谷歌浏览器下载即可。
4、本站报告下载后的文档和图纸-无水印,预览文档经过压缩,下载后原文更清晰。

本文(智慧芽:2022中美口服新冠药对比&全球3CL抑制剂专利分析报告(69页).pdf)为本站 (小时候) 主动上传,三个皮匠报告文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知三个皮匠报告文库(点击联系客服),我们立即给予删除!

温馨提示:如果因为网速或其他原因下载失败请重新下载,重复下载不扣分。
相关报告
会员购买
客服

专属顾问

商务合作

机构入驻、侵权投诉、商务合作

服务号

三个皮匠报告官方公众号

回到顶部